Newsletter | August 30, 2022

08.30.22 -- Dealing With The Complexity Of Drugs In Clinical Development

 
How To Deal With The Complexity Of Drugs In Clinical Development
 

Discover how to advance new compounds with complex chemistry through each stage of development by refining processes to give fit-for-purpose manufacturability and yields.

Implementing Flexible, Integrated Models For Phased Success
 

Learn how to provide customers leading API development services while advancing new compounds and increasingly complex chemistries, with an emphasis on manufacturability, yield optimization, safety, and efficacy.

An Approach To Integrated Small Molecule Development
 

The increasing complexity of the drugs currently in clinical development has created mounting pressure for companies hoping to overcome the challenges. Central to the pursuit is partnering with a CDMO with the capabilities and flexibility required to achieve the clinical milestones necessary for a drug’s ultimate commercial success.

The Rise Of HPAPI Molecules
 

As HPAPI molecules continue to play a growing role in new pharmaceutical products, biopharma companies will need access to flexible, sophisticated manufacturing assets to bring innovative products to market and to patients.

Regulatory Services For Accelerated Development, Commercialization
 

The increase in Breakthrough Therapy designations and other allowances for expedited regulatory review has led to ever more innovative drug products being developed under shortened timelines. But how can companies navigate today’s regulatory environment?